Shotgun proteomics analysis of SARS-CoV-2-infected cells and how it can optimize whole viral particle antigen production for vaccines
Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) has resulted in a pandemic and is continuing to spread rapidly around the globe. No effective vaccine is currently available to prevent COVID-19, and intense efforts are being invested worldwide into vaccine development. In this co...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2020-01-01
|
| Series: | Emerging Microbes and Infections |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/22221751.2020.1791737 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850150238664261632 |
|---|---|
| author | Lucia Grenga Fabrice Gallais Olivier Pible Jean-Charles Gaillard Duarte Gouveia Hélène Batina Niza Bazaline Sylvie Ruat Karen Culotta Guylaine Miotello Stéphanie Debroas Marie-Anne Roncato Gérard Steinmetz Charlotte Foissard Anne Desplan Béatrice Alpha-Bazin Christine Almunia Fabienne Gas Laurent Bellanger Jean Armengaud |
| author_facet | Lucia Grenga Fabrice Gallais Olivier Pible Jean-Charles Gaillard Duarte Gouveia Hélène Batina Niza Bazaline Sylvie Ruat Karen Culotta Guylaine Miotello Stéphanie Debroas Marie-Anne Roncato Gérard Steinmetz Charlotte Foissard Anne Desplan Béatrice Alpha-Bazin Christine Almunia Fabienne Gas Laurent Bellanger Jean Armengaud |
| author_sort | Lucia Grenga |
| collection | DOAJ |
| description | Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) has resulted in a pandemic and is continuing to spread rapidly around the globe. No effective vaccine is currently available to prevent COVID-19, and intense efforts are being invested worldwide into vaccine development. In this context, all technology platforms must overcome several challenges resulting from the use of an incompletely characterized new virus. These include finding the right conditions for virus amplification for the development of vaccines based on inactivated or attenuated whole viral particles. Here, we describe a shotgun tandem mass spectrometry workflow, the data produced can be used to guide optimization of the conditions for viral amplification. In parallel, we analysed the changes occurring in the host cell proteome following SARS-CoV-2 infection to glean information on the biological processes modulated by the virus that could be further explored as potential drug targets to deal with the pandemic. |
| format | Article |
| id | doaj-art-b03000cbf8b648f381e487a35d2ebe6e |
| institution | OA Journals |
| issn | 2222-1751 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Emerging Microbes and Infections |
| spelling | doaj-art-b03000cbf8b648f381e487a35d2ebe6e2025-08-20T02:26:37ZengTaylor & Francis GroupEmerging Microbes and Infections2222-17512020-01-01911712172110.1080/22221751.2020.1791737Shotgun proteomics analysis of SARS-CoV-2-infected cells and how it can optimize whole viral particle antigen production for vaccinesLucia Grenga0Fabrice Gallais1Olivier Pible2Jean-Charles Gaillard3Duarte Gouveia4Hélène Batina5Niza Bazaline6Sylvie Ruat7Karen Culotta8Guylaine Miotello9Stéphanie Debroas10Marie-Anne Roncato11Gérard Steinmetz12Charlotte Foissard13Anne Desplan14Béatrice Alpha-Bazin15Christine Almunia16Fabienne Gas17Laurent Bellanger18Jean Armengaud19Département Médicaments et Technologies pour la Santé (DMTS), Université Paris Saclay, CEA, INRAE, SPI Bagnols-sur-Cèze, FranceDépartement Médicaments et Technologies pour la Santé (DMTS), Université Paris Saclay, CEA, INRAE, SPI Bagnols-sur-Cèze, FranceDépartement Médicaments et Technologies pour la Santé (DMTS), Université Paris Saclay, CEA, INRAE, SPI Bagnols-sur-Cèze, FranceDépartement Médicaments et Technologies pour la Santé (DMTS), Université Paris Saclay, CEA, INRAE, SPI Bagnols-sur-Cèze, FranceDépartement Médicaments et Technologies pour la Santé (DMTS), Université Paris Saclay, CEA, INRAE, SPI Bagnols-sur-Cèze, FranceDépartement Médicaments et Technologies pour la Santé (DMTS), Université Paris Saclay, CEA, INRAE, SPI Bagnols-sur-Cèze, FranceDépartement Médicaments et Technologies pour la Santé (DMTS), Université Paris Saclay, CEA, INRAE, SPI Bagnols-sur-Cèze, FranceDépartement Médicaments et Technologies pour la Santé (DMTS), Université Paris Saclay, CEA, INRAE, SPI Bagnols-sur-Cèze, FranceDépartement Médicaments et Technologies pour la Santé (DMTS), Université Paris Saclay, CEA, INRAE, SPI Bagnols-sur-Cèze, FranceDépartement Médicaments et Technologies pour la Santé (DMTS), Université Paris Saclay, CEA, INRAE, SPI Bagnols-sur-Cèze, FranceDépartement Médicaments et Technologies pour la Santé (DMTS), Université Paris Saclay, CEA, INRAE, SPI Bagnols-sur-Cèze, FranceDépartement Médicaments et Technologies pour la Santé (DMTS), Université Paris Saclay, CEA, INRAE, SPI Bagnols-sur-Cèze, FranceDépartement Médicaments et Technologies pour la Santé (DMTS), Université Paris Saclay, CEA, INRAE, SPI Bagnols-sur-Cèze, FranceDépartement Médicaments et Technologies pour la Santé (DMTS), Université Paris Saclay, CEA, INRAE, SPI Bagnols-sur-Cèze, FranceDépartement Médicaments et Technologies pour la Santé (DMTS), Université Paris Saclay, CEA, INRAE, SPI Bagnols-sur-Cèze, FranceDépartement Médicaments et Technologies pour la Santé (DMTS), Université Paris Saclay, CEA, INRAE, SPI Bagnols-sur-Cèze, FranceDépartement Médicaments et Technologies pour la Santé (DMTS), Université Paris Saclay, CEA, INRAE, SPI Bagnols-sur-Cèze, FranceDépartement Médicaments et Technologies pour la Santé (DMTS), Université Paris Saclay, CEA, INRAE, SPI Bagnols-sur-Cèze, FranceDépartement Médicaments et Technologies pour la Santé (DMTS), Université Paris Saclay, CEA, INRAE, SPI Bagnols-sur-Cèze, FranceDépartement Médicaments et Technologies pour la Santé (DMTS), Université Paris Saclay, CEA, INRAE, SPI Bagnols-sur-Cèze, FranceSevere acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) has resulted in a pandemic and is continuing to spread rapidly around the globe. No effective vaccine is currently available to prevent COVID-19, and intense efforts are being invested worldwide into vaccine development. In this context, all technology platforms must overcome several challenges resulting from the use of an incompletely characterized new virus. These include finding the right conditions for virus amplification for the development of vaccines based on inactivated or attenuated whole viral particles. Here, we describe a shotgun tandem mass spectrometry workflow, the data produced can be used to guide optimization of the conditions for viral amplification. In parallel, we analysed the changes occurring in the host cell proteome following SARS-CoV-2 infection to glean information on the biological processes modulated by the virus that could be further explored as potential drug targets to deal with the pandemic.https://www.tandfonline.com/doi/10.1080/22221751.2020.1791737COVID-19SARS-CoV-2proteomicshost responseinfection kineticsvaccine |
| spellingShingle | Lucia Grenga Fabrice Gallais Olivier Pible Jean-Charles Gaillard Duarte Gouveia Hélène Batina Niza Bazaline Sylvie Ruat Karen Culotta Guylaine Miotello Stéphanie Debroas Marie-Anne Roncato Gérard Steinmetz Charlotte Foissard Anne Desplan Béatrice Alpha-Bazin Christine Almunia Fabienne Gas Laurent Bellanger Jean Armengaud Shotgun proteomics analysis of SARS-CoV-2-infected cells and how it can optimize whole viral particle antigen production for vaccines Emerging Microbes and Infections COVID-19 SARS-CoV-2 proteomics host response infection kinetics vaccine |
| title | Shotgun proteomics analysis of SARS-CoV-2-infected cells and how it can optimize whole viral particle antigen production for vaccines |
| title_full | Shotgun proteomics analysis of SARS-CoV-2-infected cells and how it can optimize whole viral particle antigen production for vaccines |
| title_fullStr | Shotgun proteomics analysis of SARS-CoV-2-infected cells and how it can optimize whole viral particle antigen production for vaccines |
| title_full_unstemmed | Shotgun proteomics analysis of SARS-CoV-2-infected cells and how it can optimize whole viral particle antigen production for vaccines |
| title_short | Shotgun proteomics analysis of SARS-CoV-2-infected cells and how it can optimize whole viral particle antigen production for vaccines |
| title_sort | shotgun proteomics analysis of sars cov 2 infected cells and how it can optimize whole viral particle antigen production for vaccines |
| topic | COVID-19 SARS-CoV-2 proteomics host response infection kinetics vaccine |
| url | https://www.tandfonline.com/doi/10.1080/22221751.2020.1791737 |
| work_keys_str_mv | AT luciagrenga shotgunproteomicsanalysisofsarscov2infectedcellsandhowitcanoptimizewholeviralparticleantigenproductionforvaccines AT fabricegallais shotgunproteomicsanalysisofsarscov2infectedcellsandhowitcanoptimizewholeviralparticleantigenproductionforvaccines AT olivierpible shotgunproteomicsanalysisofsarscov2infectedcellsandhowitcanoptimizewholeviralparticleantigenproductionforvaccines AT jeancharlesgaillard shotgunproteomicsanalysisofsarscov2infectedcellsandhowitcanoptimizewholeviralparticleantigenproductionforvaccines AT duartegouveia shotgunproteomicsanalysisofsarscov2infectedcellsandhowitcanoptimizewholeviralparticleantigenproductionforvaccines AT helenebatina shotgunproteomicsanalysisofsarscov2infectedcellsandhowitcanoptimizewholeviralparticleantigenproductionforvaccines AT nizabazaline shotgunproteomicsanalysisofsarscov2infectedcellsandhowitcanoptimizewholeviralparticleantigenproductionforvaccines AT sylvieruat shotgunproteomicsanalysisofsarscov2infectedcellsandhowitcanoptimizewholeviralparticleantigenproductionforvaccines AT karenculotta shotgunproteomicsanalysisofsarscov2infectedcellsandhowitcanoptimizewholeviralparticleantigenproductionforvaccines AT guylainemiotello shotgunproteomicsanalysisofsarscov2infectedcellsandhowitcanoptimizewholeviralparticleantigenproductionforvaccines AT stephaniedebroas shotgunproteomicsanalysisofsarscov2infectedcellsandhowitcanoptimizewholeviralparticleantigenproductionforvaccines AT marieanneroncato shotgunproteomicsanalysisofsarscov2infectedcellsandhowitcanoptimizewholeviralparticleantigenproductionforvaccines AT gerardsteinmetz shotgunproteomicsanalysisofsarscov2infectedcellsandhowitcanoptimizewholeviralparticleantigenproductionforvaccines AT charlottefoissard shotgunproteomicsanalysisofsarscov2infectedcellsandhowitcanoptimizewholeviralparticleantigenproductionforvaccines AT annedesplan shotgunproteomicsanalysisofsarscov2infectedcellsandhowitcanoptimizewholeviralparticleantigenproductionforvaccines AT beatricealphabazin shotgunproteomicsanalysisofsarscov2infectedcellsandhowitcanoptimizewholeviralparticleantigenproductionforvaccines AT christinealmunia shotgunproteomicsanalysisofsarscov2infectedcellsandhowitcanoptimizewholeviralparticleantigenproductionforvaccines AT fabiennegas shotgunproteomicsanalysisofsarscov2infectedcellsandhowitcanoptimizewholeviralparticleantigenproductionforvaccines AT laurentbellanger shotgunproteomicsanalysisofsarscov2infectedcellsandhowitcanoptimizewholeviralparticleantigenproductionforvaccines AT jeanarmengaud shotgunproteomicsanalysisofsarscov2infectedcellsandhowitcanoptimizewholeviralparticleantigenproductionforvaccines |